Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (HP) (13C) in Castration-Resistant Prostate Cancer

Prostate Cancer Clinical Trial

— MR  

Official title:

Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (13C) as a Predictive Biomarker of Response to Androgen Signaling Inhibitors in Castration-Resistant Prostate Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02911467
• Other study ID #: 15559
• Secondary ID: 5R01CA166655-04
• Status: Terminated
• Phase: Phase 1
• Start date: November 8, 2016
• Est. completion date: July 20, 2020

Study information

• Verified date: July 2020
• Source: University of California, San Francisco
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective imaging study evaluating the utility of baseline metabolic MR imaging with Hyperpolarized Pyruvate (HP) (13C) as a predictive response biomarker to androgen signaling inhibition in patients with castration-resistant prostate cancer.

Description:

This is a prospective imaging study evaluating the utility of baseline metabolic MR imaging as a predictive response biomarker to androgen signaling inhibition in patients with castration-resistant prostate cancer. Patients with a target lesion that is amenable for metabolic MR imaging will be eligible for study participation. Patients will undergo baseline metabolic MR imaging with Hyperpolarized Pyruvate C-13 pyruvate followed by initiation of androgen signaling inhibition (either as standard of care or as part of clinical trial; including abiraterone and/or enzalutamide treatment). Patient will subsequently undergo repeat metabolic MR scan after 28 days (+/- 7 days) of therapy. For those without primarily refractory disease, a third metabolic MR scan will be completed at the time of radiographic disease progression by The Prostate Cancer Clinical Trials Working Group 2 (PCWG2) criteria. MR- or CT-guided tumor biopsies are optional at baseline and at the time of disease progression.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 8
• Est. completion date: July 20, 2020
• Est. primary completion date: July 20, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Biopsy-proven prostate cancer.

2. Progressive, castration-resistant disease according to PCWG2 criteria.

3. Planned treatment with an androgen signaling inhibitor (e.g., abiraterone, enzalutamide, apalutamide (ARN-509)). Patients must not be receiving androgen signaling inhibitor at the time of the baseline MR scan. Combination treatment (e.g., androgen signaling inhibitor in conjunction with another systemic treatment) is allowed.

4. Presence of at least one target lesion detected by standard staging scans that, in the judgment of Study Investigators, would be amenable to hyperpolarized C-13 pyruvate/metabolic MR imaging:

• Soft tissue/visceral organ target lesions must measure at 1.5 cm in long axis diameter on CT or MRI.

• Target lesions in the bone must be visualized by CT or MRI (lesions present only on bone scan do not qualify).

• For patients with target lesion in prostate/prostatic bed:

i. No contra-indications to endorectal coil insertion (e.g., patients with a prior abdominoperineal resection of the rectum or latex allergy).

ii. No prior local treatment to the selected lesion. Patients who have received prior radiation or ablative therapy to the prostate will be required to have biopsy-proven evidence of disease recurrence following completion of local therapy.

5. The subject is able and willing to comply with study procedures and provide signed and dated informed consent.

6. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

7. Adequate organ function, including absolute neutrophil count (ANC) = 1500 cells/µL, hemoglobin = 9.0 gm/dL, platelets = 75,000 cells/µL, creatinine < 1.5 x ULN or estimated creatinine clearance = 50 mL/min (by the Cockcroft Gault equation), bilirubin <1.5x ULN (unless Gilbert's is suspected in which case total bilirubin < 3 x ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 1.5x ULN.

8. For patients undergoing optional tumor biopsy:

• No history of bleeding diathesis.

• Patients on anti-coagulation they must be able to safely stop treatment for purposes of tumor biopsy.

9. For patients with partners of childbearing potential, willing to use adequate contraception for one month after undergoing HP pyruvate infusion.

10. Patients must have prior bilateral orchiectomy or be on continuous luteinizing-hormone releasing hormone (LHRH) analogue therapy for the duration of study.

11. Castrate level of serum testosterone (< 50 ng/dL) at study entry.

Exclusion Criteria:

1. Patients who because of age, general medical or psychiatric condition, or physiologic status cannot give valid informed consent.

2. Patients unwilling or unable to undergo MR imaging, including patients with contra-indications to MRI, such as cardiac pacemakers or non-compatible intracranial vascular clips.

3. Metallic hip implant or any other metallic implant or device that distorts local magnetic field and compromises the quality of MR imaging.

4. Poorly controlled hypertension, defined as systolic blood pressure at study entry greater than 160 mm Hg or diastolic blood pressure greater than 100 mm Hg. The addition of anti-hypertensives to control blood pressure is allowed.

5. Congestive heart failure or New York Heart Association (NYHA) status = 2.

6. A history of clinically significant EKG abnormalities, including QT prolongation (QTcF > 500 ms), a family history of prolonged QT interval syndrome, or myocardial infarction (MI) within 6 months of study entry. Patients with rate-controlled atrial fibrillation/flutter will be allowed on study.

7. Any condition that, in the opinion of the Principal Investigator, would impair the patient's ability to comply with study procedures.

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• Pyruvate (13C)
Pyruvate injection followed by an MRI scan.

Device:
• MRI
MRI scan following the Pyruvate injection

Locations

Country	Name	City	State
United States	University of California, San Francisco	San Francisco	California

Sponsors (2)

Lead Sponsor	Collaborator
Rahul Aggarwal	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean difference in baseline intra-tumoral peak lac/pyr ratio on HP C-13 MRI in ASI-refractory versus ASI-responsive CRPC tumors	ASI-refractory disease is defined as progression by PCWG2 criteria within 6 months of treatment initiation. ASI-responsive disease includes all other tumors not meeting this criterion. A two sample t-test will be used to compare the mean intra-tumoral HP lac/pyr ratio between treatment-refractory versus treatment-responsive tumors. If a non-parametric distribution is observed, a Mann-Whitney test may also be used to compare the two groups.	Up to 6 months
Secondary	Association between change from baseline in peak intra-tumoral HP lac/pyr ratio after 28 days of ASI treatment with subsequent clinical outcomes on ASI treatment	For the purposes of analyzing the association between early change in lac/pyr ratio on HP MRI with subsequent clinical outcomes, the cohort will be dichotomized according to whether follow up scan 4 weeks (28 days) after starting treatment demonstrates increase versus decrease in peak intratumoral lac/pyr ratio compared to baseline. The Prostate-specific antigen (PSA) response rate (PCWG2 criteria) will be compared between dichotomized groups using the chi-squared test. The log rank test will be used to compare the radiographic progression-free survival between the two groups	Up to 28 days
Secondary	Mean percent change from baseline in peak intra-tumoral HP lac/pyr ratio on repeat metabolic MRI	The mean percent change from baseline in peak intra-tumoral HP lac/pyr ratio to repeat metabolic MRI obtained at the time of radiographic disease progression by PCWG2 criteria will be descriptively reported for the entire study cohort and for the subgroups of patients with treatment- refractory and treatment-responsive prostate cance	Up to 6 months
Secondary	Baseline peak intra-tumoral HP lac/pyr ratio cut-point that most accurately predicts for response versus refractoriness to subsequent ASI treatment	Receiver-operating-curve will be applied to determine the optimal cut-point of peak intra-tumoral lac/pyr values on MRI that accurately distinguish treatment-refractory versus treatment responsive prostate cancer.	Baseline
Secondary	Frequency of clinically significant changes in safety variables over time	Safety endpoints include monitoring for the occurrence of treatment-emergent AEs. Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology (Toxicity) Criteria for Adverse Events (CTCAE) version 4.0	Up to 6 months
Secondary	Mean Intra-patient reproducibility of HP lac/pyr ratio	Intra-patient reproducibility of HP lac/pyr ratio for patients who undergo repeated dose imaging studies, as descriptively reported using summary statistics	Up to 6 months